Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Review Article Volume 7 Issue 7

COVID-19 Associated Cholangiopathy

Hugh James Freeman*

Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada

*Corresponding Author: Hugh James Freeman, Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada.

Received: May 02, 2023; Published: June 13, 2023


A newly described complication of severe COVID-19 is an unusual, but late-appearing form of cholangiopathy associated with a “secondary” form of sclerosing cholangitis. The aim of this evaluation was to review literature related to this disorder. Clinical features include elevated alkaline phosphatase with imaging changes typical of bile duct obstruction. In some, this was complicated by progressive jaundice often accompanied by changes of large duct obstruction and biliary casts. The precise mechanism for late biliary ductal injury still requires elucidation. In addition, Covid-19 patients require long-term follow-up, as changes may only develop late in the clinical course. Moreover, treatment has been difficult with progression to fulminant hepatic failure and requirement for liver transplantation.

Keywords: COVID-19 Bile Duct Disease; Virus-associated Cholangiopathy; Cholestatic Liver Disease; SARS-CoV-2 Infection; Coronavirus Cholestasis


  1. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
  2. Barouch DH. “Covid-19 vaccines—immunity, variants, boosters”. New England Journal of Medicine 387 (2022): 1011-1020.
  3. Sharif N., et al. “Efficacy, immunogenicity and safety of COVID-19 vaccines: a systemic review and meta-analysis”. Frontiers in Immunology 12 (2021): 714170.
  4. Chen Y., et al. “New-onset autoimmune phenomena post COVID-19 vaccination”. Immunology 165 (2021): 386-401.
  5. Freeman HJ. “Collagenous colitis associated with novel sprue-like intestinal diseases”. Gastroenterology Hepatology Bedside to Bench In press, (2023).
  6. Bril F., et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccination: causality or casualty?” Journal of Hepatology 75 (2021): 222-224.
  7. Shroff H., et al. “Liver injury following SARS-CoV-2 vaccination: a multicenter case series”. Journal of Hepatology 76 (2022): 211-214.
  8. Phipps MM., et al. “Acute liver injury in COVID-19. Prevalence and association with clinical outcomes in a large US cohort”. Hepatology 72 (2020): 807-817.
  9. Efe C., et al. “Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome”. Hepatology (2022).
  10. Efe C., et al. “Liver transplantation following severe acute respiratory syndrome-coronavirus-2 vaccination-induced liver failure”. Hepatology 75 (2022):1669-1671.
  11. Faruqui S., et al. “ Cholangiopathy after severe COVID-19: clinical features and prognostic implications”. American Journal of Gastroenterology 116 (2021): 1414-1425.
  12. Butikofer S., et al. “Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19”. Liver International 41 (2021): 2404-2417.
  13. Freeman HJ. “Covid-19 diarrhea”. International Journal of Celiac Disease 8 (2020): 60-63.
  14. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis”. Journal of Pathology 203 (2004): 631-637.
  15. Cabaliero-Alvarado J., et al. “Post-COVID cholangiopathy: a narrative review”. Gastroenterology and Hepatology (2022):S0210-5705(22)00221-7.
  16. Shih AR., et al. “Persistent cholestatic injury and secondary sclerosing cholangitis in COVID-19 patients”. Archives of Pathology and Laboratory Medicine 146 (2022): 1184-1193.
  17. Ferreira FB., et al. “COVID-19-associated secondary sclerosing cholangitis—a case series”. Clinical Research Hepatology Gastroenterology 46 (2022):102048.
  18. Lee A., et al. “Liver transplantation for post-COVID-19 sclerosing cholangitis”. British Medical Journal Case Reports 14 (2021): e244168.
  19. Machado MC., et al. “Post-COVID-19 secondary sclerosing cholangitis: a rare but severe condition with no treatment besides liver transplantation”. American Journal of Case Reports (2022):e936250.
  20. Bazerbachi F., et al. “Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy”. Revista Espanola de Enfermedades Digestives (2022).
  21. Soldera J., et al. “Billiary casts in post-COVID-19 cholangiography”. Gastroenterology Hepatology 46 (2023): 319-320.


Citation: Hugh James Freeman. “COVID-19 Associated Cholangiopathy”.Acta Scientific Medical Sciences 7.7 (2023): 48-50.


Copyright: © 2023 Hugh James Freeman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US